Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic org...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Targher, G. [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2016transfer abstract |
|---|
| Schlagwörter: |
|---|
| Umfang: |
15 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Serological and molecular evaluation of - Uy, Mary Rose D. ELSEVIER, 2018, Issy-les-Moulineaux |
|---|---|
| Übergeordnetes Werk: |
volume:42 ; year:2016 ; number:3 ; pages:142-156 ; extent:15 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.diabet.2016.04.002 |
|---|
| Katalog-ID: |
ELV019690606 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV019690606 | ||
| 003 | DE-627 | ||
| 005 | 20230625130455.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2016 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.diabet.2016.04.002 |2 doi | |
| 028 | 5 | 2 | |a GBVA2016019000006.pica |
| 035 | |a (DE-627)ELV019690606 | ||
| 035 | |a (ELSEVIER)S1262-3636(16)30394-9 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |a 570 |q VZ |
| 084 | |a 44.43 |2 bkl | ||
| 084 | |a 44.75 |2 bkl | ||
| 100 | 1 | |a Targher, G. |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? |
| 264 | 1 | |c 2016transfer abstract | |
| 300 | |a 15 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. | ||
| 520 | |a Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. | ||
| 650 | 7 | |a Type 2 diabetes |2 Elsevier | |
| 650 | 7 | |a NAFLD |2 Elsevier | |
| 650 | 7 | |a Non-alcoholic fatty liver disease |2 Elsevier | |
| 650 | 7 | |a Epidemiology |2 Elsevier | |
| 650 | 7 | |a Diabetes risk |2 Elsevier | |
| 700 | 1 | |a Marchesini, G. |4 oth | |
| 700 | 1 | |a Byrne, C.D. |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier Masson |a Uy, Mary Rose D. ELSEVIER |t Serological and molecular evaluation of |d 2018 |g Issy-les-Moulineaux |w (DE-627)ELV001177605 |
| 773 | 1 | 8 | |g volume:42 |g year:2016 |g number:3 |g pages:142-156 |g extent:15 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.diabet.2016.04.002 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.43 |j Medizinische Mikrobiologie |q VZ |
| 936 | b | k | |a 44.75 |j Infektionskrankheiten |j parasitäre Krankheiten |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 42 |j 2016 |e 3 |h 142-156 |g 15 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
g t gt |
|---|---|
| matchkey_str |
targhergmarchesinigbyrnecd:2016----:ikfyedaeeiptetwtnnlooiftyiedsaeasl |
| hierarchy_sort_str |
2016transfer abstract |
| bklnumber |
44.43 44.75 |
| publishDate |
2016 |
| allfields |
10.1016/j.diabet.2016.04.002 doi GBVA2016019000006.pica (DE-627)ELV019690606 (ELSEVIER)S1262-3636(16)30394-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Targher, G. verfasserin aut Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? 2016transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. Type 2 diabetes Elsevier NAFLD Elsevier Non-alcoholic fatty liver disease Elsevier Epidemiology Elsevier Diabetes risk Elsevier Marchesini, G. oth Byrne, C.D. oth Enthalten in Elsevier Masson Uy, Mary Rose D. ELSEVIER Serological and molecular evaluation of 2018 Issy-les-Moulineaux (DE-627)ELV001177605 volume:42 year:2016 number:3 pages:142-156 extent:15 https://doi.org/10.1016/j.diabet.2016.04.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.43 Medizinische Mikrobiologie VZ 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 42 2016 3 142-156 15 045F 610 |
| spelling |
10.1016/j.diabet.2016.04.002 doi GBVA2016019000006.pica (DE-627)ELV019690606 (ELSEVIER)S1262-3636(16)30394-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Targher, G. verfasserin aut Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? 2016transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. Type 2 diabetes Elsevier NAFLD Elsevier Non-alcoholic fatty liver disease Elsevier Epidemiology Elsevier Diabetes risk Elsevier Marchesini, G. oth Byrne, C.D. oth Enthalten in Elsevier Masson Uy, Mary Rose D. ELSEVIER Serological and molecular evaluation of 2018 Issy-les-Moulineaux (DE-627)ELV001177605 volume:42 year:2016 number:3 pages:142-156 extent:15 https://doi.org/10.1016/j.diabet.2016.04.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.43 Medizinische Mikrobiologie VZ 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 42 2016 3 142-156 15 045F 610 |
| allfields_unstemmed |
10.1016/j.diabet.2016.04.002 doi GBVA2016019000006.pica (DE-627)ELV019690606 (ELSEVIER)S1262-3636(16)30394-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Targher, G. verfasserin aut Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? 2016transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. Type 2 diabetes Elsevier NAFLD Elsevier Non-alcoholic fatty liver disease Elsevier Epidemiology Elsevier Diabetes risk Elsevier Marchesini, G. oth Byrne, C.D. oth Enthalten in Elsevier Masson Uy, Mary Rose D. ELSEVIER Serological and molecular evaluation of 2018 Issy-les-Moulineaux (DE-627)ELV001177605 volume:42 year:2016 number:3 pages:142-156 extent:15 https://doi.org/10.1016/j.diabet.2016.04.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.43 Medizinische Mikrobiologie VZ 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 42 2016 3 142-156 15 045F 610 |
| allfieldsGer |
10.1016/j.diabet.2016.04.002 doi GBVA2016019000006.pica (DE-627)ELV019690606 (ELSEVIER)S1262-3636(16)30394-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Targher, G. verfasserin aut Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? 2016transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. Type 2 diabetes Elsevier NAFLD Elsevier Non-alcoholic fatty liver disease Elsevier Epidemiology Elsevier Diabetes risk Elsevier Marchesini, G. oth Byrne, C.D. oth Enthalten in Elsevier Masson Uy, Mary Rose D. ELSEVIER Serological and molecular evaluation of 2018 Issy-les-Moulineaux (DE-627)ELV001177605 volume:42 year:2016 number:3 pages:142-156 extent:15 https://doi.org/10.1016/j.diabet.2016.04.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.43 Medizinische Mikrobiologie VZ 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 42 2016 3 142-156 15 045F 610 |
| allfieldsSound |
10.1016/j.diabet.2016.04.002 doi GBVA2016019000006.pica (DE-627)ELV019690606 (ELSEVIER)S1262-3636(16)30394-9 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Targher, G. verfasserin aut Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? 2016transfer abstract 15 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. Type 2 diabetes Elsevier NAFLD Elsevier Non-alcoholic fatty liver disease Elsevier Epidemiology Elsevier Diabetes risk Elsevier Marchesini, G. oth Byrne, C.D. oth Enthalten in Elsevier Masson Uy, Mary Rose D. ELSEVIER Serological and molecular evaluation of 2018 Issy-les-Moulineaux (DE-627)ELV001177605 volume:42 year:2016 number:3 pages:142-156 extent:15 https://doi.org/10.1016/j.diabet.2016.04.002 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA 44.43 Medizinische Mikrobiologie VZ 44.75 Infektionskrankheiten parasitäre Krankheiten Medizin VZ AR 42 2016 3 142-156 15 045F 610 |
| language |
English |
| source |
Enthalten in Serological and molecular evaluation of Issy-les-Moulineaux volume:42 year:2016 number:3 pages:142-156 extent:15 |
| sourceStr |
Enthalten in Serological and molecular evaluation of Issy-les-Moulineaux volume:42 year:2016 number:3 pages:142-156 extent:15 |
| format_phy_str_mv |
Article |
| bklname |
Medizinische Mikrobiologie Infektionskrankheiten parasitäre Krankheiten |
| institution |
findex.gbv.de |
| topic_facet |
Type 2 diabetes NAFLD Non-alcoholic fatty liver disease Epidemiology Diabetes risk |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Serological and molecular evaluation of |
| authorswithroles_txt_mv |
Targher, G. @@aut@@ Marchesini, G. @@oth@@ Byrne, C.D. @@oth@@ |
| publishDateDaySort_date |
2016-01-01T00:00:00Z |
| hierarchy_top_id |
ELV001177605 |
| dewey-sort |
3610 |
| id |
ELV019690606 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV019690606</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625130455.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.diabet.2016.04.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016019000006.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV019690606</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1262-3636(16)30394-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.43</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.75</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Targher, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Type 2 diabetes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NAFLD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-alcoholic fatty liver disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epidemiology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Diabetes risk</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marchesini, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Byrne, C.D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Masson</subfield><subfield code="a">Uy, Mary Rose D. ELSEVIER</subfield><subfield code="t">Serological and molecular evaluation of</subfield><subfield code="d">2018</subfield><subfield code="g">Issy-les-Moulineaux</subfield><subfield code="w">(DE-627)ELV001177605</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:42</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:142-156</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.diabet.2016.04.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.43</subfield><subfield code="j">Medizinische Mikrobiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.75</subfield><subfield code="j">Infektionskrankheiten</subfield><subfield code="j">parasitäre Krankheiten</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">42</subfield><subfield code="j">2016</subfield><subfield code="e">3</subfield><subfield code="h">142-156</subfield><subfield code="g">15</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Targher, G. |
| spellingShingle |
Targher, G. ddc 610 bkl 44.43 bkl 44.75 Elsevier Type 2 diabetes Elsevier NAFLD Elsevier Non-alcoholic fatty liver disease Elsevier Epidemiology Elsevier Diabetes risk Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? |
| authorStr |
Targher, G. |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV001177605 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health 570 - Life sciences; biology |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? Type 2 diabetes Elsevier NAFLD Elsevier Non-alcoholic fatty liver disease Elsevier Epidemiology Elsevier Diabetes risk Elsevier |
| topic |
ddc 610 bkl 44.43 bkl 44.75 Elsevier Type 2 diabetes Elsevier NAFLD Elsevier Non-alcoholic fatty liver disease Elsevier Epidemiology Elsevier Diabetes risk |
| topic_unstemmed |
ddc 610 bkl 44.43 bkl 44.75 Elsevier Type 2 diabetes Elsevier NAFLD Elsevier Non-alcoholic fatty liver disease Elsevier Epidemiology Elsevier Diabetes risk |
| topic_browse |
ddc 610 bkl 44.43 bkl 44.75 Elsevier Type 2 diabetes Elsevier NAFLD Elsevier Non-alcoholic fatty liver disease Elsevier Epidemiology Elsevier Diabetes risk |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
g m gm c b cb |
| hierarchy_parent_title |
Serological and molecular evaluation of |
| hierarchy_parent_id |
ELV001177605 |
| dewey-tens |
610 - Medicine & health 570 - Life sciences; biology |
| hierarchy_top_title |
Serological and molecular evaluation of |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV001177605 |
| title |
Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? |
| ctrlnum |
(DE-627)ELV019690606 (ELSEVIER)S1262-3636(16)30394-9 |
| title_full |
Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? |
| author_sort |
Targher, G. |
| journal |
Serological and molecular evaluation of |
| journalStr |
Serological and molecular evaluation of |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology 500 - Science |
| recordtype |
marc |
| publishDateSort |
2016 |
| contenttype_str_mv |
zzz |
| container_start_page |
142 |
| author_browse |
Targher, G. |
| container_volume |
42 |
| physical |
15 |
| class |
610 610 DE-600 610 570 VZ 44.43 bkl 44.75 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Targher, G. |
| doi_str_mv |
10.1016/j.diabet.2016.04.002 |
| dewey-full |
610 570 |
| title_sort |
risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: causal association or epiphenomenon? |
| title_auth |
Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? |
| abstract |
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. |
| abstractGer |
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. |
| abstract_unstemmed |
Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA |
| container_issue |
3 |
| title_short |
Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon? |
| url |
https://doi.org/10.1016/j.diabet.2016.04.002 |
| remote_bool |
true |
| author2 |
Marchesini, G. Byrne, C.D. |
| author2Str |
Marchesini, G. Byrne, C.D. |
| ppnlink |
ELV001177605 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth |
| doi_str |
10.1016/j.diabet.2016.04.002 |
| up_date |
2024-07-06T22:06:30.337Z |
| _version_ |
1803869057542258688 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV019690606</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230625130455.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2016 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.diabet.2016.04.002</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2016019000006.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV019690606</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1262-3636(16)30394-9</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="a">570</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.43</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.75</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Targher, G.</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Risk of type 2 diabetes in patients with non-alcoholic fatty liver disease: Causal association or epiphenomenon?</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2016transfer abstract</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">15</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes.</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Non-alcoholic fatty liver disease (NAFLD) has become the leading cause of chronic liver diseases worldwide, causing considerable liver-related mortality and morbidity. Over the last 10years, it has also become increasingly evident that NAFLD is a multisystem disease, affecting many extra-hepatic organ systems and interacting with the regulation of multiple metabolic pathways. NAFLD is potentially involved in the aetiology and pathogenesis of type 2 diabetes via its direct contribution to hepatic/peripheral insulin resistance and the systemic release of multiple hepatokines that may adversely affect glucose metabolism and insulin action. In this updated review, we discuss the rapidly expanding body of clinical and epidemiological evidence that supports a strong link between NAFLD and the risk of developing type 2 diabetes. We also briefly examine the conventional and the more innovative pharmacological approaches for the treatment of NAFLD that may influence the risk of developing type 2 diabetes.</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Type 2 diabetes</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">NAFLD</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Non-alcoholic fatty liver disease</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epidemiology</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Diabetes risk</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marchesini, G.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Byrne, C.D.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier Masson</subfield><subfield code="a">Uy, Mary Rose D. ELSEVIER</subfield><subfield code="t">Serological and molecular evaluation of</subfield><subfield code="d">2018</subfield><subfield code="g">Issy-les-Moulineaux</subfield><subfield code="w">(DE-627)ELV001177605</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:42</subfield><subfield code="g">year:2016</subfield><subfield code="g">number:3</subfield><subfield code="g">pages:142-156</subfield><subfield code="g">extent:15</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.diabet.2016.04.002</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.43</subfield><subfield code="j">Medizinische Mikrobiologie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.75</subfield><subfield code="j">Infektionskrankheiten</subfield><subfield code="j">parasitäre Krankheiten</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">42</subfield><subfield code="j">2016</subfield><subfield code="e">3</subfield><subfield code="h">142-156</subfield><subfield code="g">15</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.400403 |